IOP after ICRS™ implantation for myopic correction

D. K. Chitkara, E. S. Rosen, Penny Asbell, R. L. Abbott, T. E. Bums, D. S. Dume, R. L. Lindstrom, D. J. Schanzlin

Research output: Contribution to journalArticle

Abstract

Purpose. To assess the impact, if any. of ICRS (Intrastromal Corneal Ring Segment) implantation on intraocular pressure (IOP), patients enrolled in the U.S. Phase II and European ICRS clinical trials were evaluated. Methods. Individuals with IOP measurements outside the normal 10 to 21 mmHg range, or with a history of glaucoma, were excluded from the trials. To date, 148 U.S. patients and 47 European patients have received the ICRS in one eye. An approximately equal distribution of five ICRS thicknesses (0.25, 0.30, 0.35, 0.40 and 0.45 mm) were implanted. IOP was measured in both eyes preop and at each postop exam using a TonoPen XL, or equivalent hand-held tonometer. Results. Using available U.S. Phase II trial data, the mean (SEM) IOP were calculated {Preop: 15.5 mmHg (0.29); Day 1: 14.3 mmHg (0.31); < Month 2: 17.4 mmHg (0.32); and Month 3: 13.3 mmHg (0.35)]. The percentage of individual patients falling within the normal range was also calculated [Preop: 99% (101/102); Day 1: 96% (96/98); < Month 2: 90% (91/101); Month 3: 91% (90/99)]. All patients with an increase/decrease outside the normal range at Month 3 exhibited a similar increase/decrease in the nonoperative eye. The was no statistically significant ICRS thickness effect at any of the time points (p >0.36). Conclusions. The mean IOP values remained well within the normal range at all time points. The increase and decrease in TOP relative to baseline for all patients appeared to be transient in nature and without a systemic pattern. The ICRS does not appear to compromise normal IOP status and is well-tolerated by the cornea. Data collection is ongoing, and combined results from the European and U.S. trials will be reported. Cf 268.

Original languageEnglish (US)
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

Intraocular Pressure
Glaucoma
Cornea
Reference Values
Hand
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Chitkara, D. K., Rosen, E. S., Asbell, P., Abbott, R. L., Bums, T. E., Dume, D. S., ... Schanzlin, D. J. (1997). IOP after ICRS™ implantation for myopic correction. Investigative Ophthalmology and Visual Science, 38(4).

IOP after ICRS™ implantation for myopic correction. / Chitkara, D. K.; Rosen, E. S.; Asbell, Penny; Abbott, R. L.; Bums, T. E.; Dume, D. S.; Lindstrom, R. L.; Schanzlin, D. J.

In: Investigative Ophthalmology and Visual Science, Vol. 38, No. 4, 01.12.1997.

Research output: Contribution to journalArticle

Chitkara, DK, Rosen, ES, Asbell, P, Abbott, RL, Bums, TE, Dume, DS, Lindstrom, RL & Schanzlin, DJ 1997, 'IOP after ICRS™ implantation for myopic correction', Investigative Ophthalmology and Visual Science, vol. 38, no. 4.
Chitkara DK, Rosen ES, Asbell P, Abbott RL, Bums TE, Dume DS et al. IOP after ICRS™ implantation for myopic correction. Investigative Ophthalmology and Visual Science. 1997 Dec 1;38(4).
Chitkara, D. K. ; Rosen, E. S. ; Asbell, Penny ; Abbott, R. L. ; Bums, T. E. ; Dume, D. S. ; Lindstrom, R. L. ; Schanzlin, D. J. / IOP after ICRS™ implantation for myopic correction. In: Investigative Ophthalmology and Visual Science. 1997 ; Vol. 38, No. 4.
@article{b6536baa27cf4560a4a52d342bf1360f,
title = "IOP after ICRS™ implantation for myopic correction",
abstract = "Purpose. To assess the impact, if any. of ICRS (Intrastromal Corneal Ring Segment) implantation on intraocular pressure (IOP), patients enrolled in the U.S. Phase II and European ICRS clinical trials were evaluated. Methods. Individuals with IOP measurements outside the normal 10 to 21 mmHg range, or with a history of glaucoma, were excluded from the trials. To date, 148 U.S. patients and 47 European patients have received the ICRS in one eye. An approximately equal distribution of five ICRS thicknesses (0.25, 0.30, 0.35, 0.40 and 0.45 mm) were implanted. IOP was measured in both eyes preop and at each postop exam using a TonoPen XL, or equivalent hand-held tonometer. Results. Using available U.S. Phase II trial data, the mean (SEM) IOP were calculated {Preop: 15.5 mmHg (0.29); Day 1: 14.3 mmHg (0.31); < Month 2: 17.4 mmHg (0.32); and Month 3: 13.3 mmHg (0.35)]. The percentage of individual patients falling within the normal range was also calculated [Preop: 99{\%} (101/102); Day 1: 96{\%} (96/98); < Month 2: 90{\%} (91/101); Month 3: 91{\%} (90/99)]. All patients with an increase/decrease outside the normal range at Month 3 exhibited a similar increase/decrease in the nonoperative eye. The was no statistically significant ICRS thickness effect at any of the time points (p >0.36). Conclusions. The mean IOP values remained well within the normal range at all time points. The increase and decrease in TOP relative to baseline for all patients appeared to be transient in nature and without a systemic pattern. The ICRS does not appear to compromise normal IOP status and is well-tolerated by the cornea. Data collection is ongoing, and combined results from the European and U.S. trials will be reported. Cf 268.",
author = "Chitkara, {D. K.} and Rosen, {E. S.} and Penny Asbell and Abbott, {R. L.} and Bums, {T. E.} and Dume, {D. S.} and Lindstrom, {R. L.} and Schanzlin, {D. J.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "38",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - IOP after ICRS™ implantation for myopic correction

AU - Chitkara, D. K.

AU - Rosen, E. S.

AU - Asbell, Penny

AU - Abbott, R. L.

AU - Bums, T. E.

AU - Dume, D. S.

AU - Lindstrom, R. L.

AU - Schanzlin, D. J.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose. To assess the impact, if any. of ICRS (Intrastromal Corneal Ring Segment) implantation on intraocular pressure (IOP), patients enrolled in the U.S. Phase II and European ICRS clinical trials were evaluated. Methods. Individuals with IOP measurements outside the normal 10 to 21 mmHg range, or with a history of glaucoma, were excluded from the trials. To date, 148 U.S. patients and 47 European patients have received the ICRS in one eye. An approximately equal distribution of five ICRS thicknesses (0.25, 0.30, 0.35, 0.40 and 0.45 mm) were implanted. IOP was measured in both eyes preop and at each postop exam using a TonoPen XL, or equivalent hand-held tonometer. Results. Using available U.S. Phase II trial data, the mean (SEM) IOP were calculated {Preop: 15.5 mmHg (0.29); Day 1: 14.3 mmHg (0.31); < Month 2: 17.4 mmHg (0.32); and Month 3: 13.3 mmHg (0.35)]. The percentage of individual patients falling within the normal range was also calculated [Preop: 99% (101/102); Day 1: 96% (96/98); < Month 2: 90% (91/101); Month 3: 91% (90/99)]. All patients with an increase/decrease outside the normal range at Month 3 exhibited a similar increase/decrease in the nonoperative eye. The was no statistically significant ICRS thickness effect at any of the time points (p >0.36). Conclusions. The mean IOP values remained well within the normal range at all time points. The increase and decrease in TOP relative to baseline for all patients appeared to be transient in nature and without a systemic pattern. The ICRS does not appear to compromise normal IOP status and is well-tolerated by the cornea. Data collection is ongoing, and combined results from the European and U.S. trials will be reported. Cf 268.

AB - Purpose. To assess the impact, if any. of ICRS (Intrastromal Corneal Ring Segment) implantation on intraocular pressure (IOP), patients enrolled in the U.S. Phase II and European ICRS clinical trials were evaluated. Methods. Individuals with IOP measurements outside the normal 10 to 21 mmHg range, or with a history of glaucoma, were excluded from the trials. To date, 148 U.S. patients and 47 European patients have received the ICRS in one eye. An approximately equal distribution of five ICRS thicknesses (0.25, 0.30, 0.35, 0.40 and 0.45 mm) were implanted. IOP was measured in both eyes preop and at each postop exam using a TonoPen XL, or equivalent hand-held tonometer. Results. Using available U.S. Phase II trial data, the mean (SEM) IOP were calculated {Preop: 15.5 mmHg (0.29); Day 1: 14.3 mmHg (0.31); < Month 2: 17.4 mmHg (0.32); and Month 3: 13.3 mmHg (0.35)]. The percentage of individual patients falling within the normal range was also calculated [Preop: 99% (101/102); Day 1: 96% (96/98); < Month 2: 90% (91/101); Month 3: 91% (90/99)]. All patients with an increase/decrease outside the normal range at Month 3 exhibited a similar increase/decrease in the nonoperative eye. The was no statistically significant ICRS thickness effect at any of the time points (p >0.36). Conclusions. The mean IOP values remained well within the normal range at all time points. The increase and decrease in TOP relative to baseline for all patients appeared to be transient in nature and without a systemic pattern. The ICRS does not appear to compromise normal IOP status and is well-tolerated by the cornea. Data collection is ongoing, and combined results from the European and U.S. trials will be reported. Cf 268.

UR - http://www.scopus.com/inward/record.url?scp=33749209306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749209306&partnerID=8YFLogxK

M3 - Article

VL - 38

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -